MKI67 and neoplasm: Moreover, the study highlights the importance of continuing palbociclib treatment, as early palbociclib withdrawal led to a Ki67 rebound after surgery.678 In line with the NeopalAna study, the DxCARTES Phase II trial results also showed that palbociclib plus letrozole-driven downstaging is independent of the tumor baseline molecular characteristics.679